Abstract
The design and development of novel biological drugs are among the most exciting new areas of biotechnology which are gaining the attention of scientists. In the last few decades several fabrication processes have been proposed and developed for the production of recombinant growth factors. However, traditional production processes have several limitations in terms of scale- up, cost-efficiency and purity grade of the proteins. In the present study, we propose for the first time the proof-of-concept of large-scale production of growth factors in plants as a new alternative to other production processes. We have decided to select vascular endothelial growth factor (VEGF) as model assuming its key role in cell survival and regenerative medicine. Results show that the present protocol is efficient to scale up a purification procedure of rh VEGF isoform 165 in Nicotiana benthamiana plants. Our procedure resulted in dimeric VEGF protein with high purity degree and yield, which showed full biological activity over endothelial and epithelial cells, suggesting great potential for its use in regenerative medicine. This protein could be exploited not only in tissue repair and regeneration but also as a biologically active ingredient in dermocosmetics.
Keywords: Growth Factor, recombinant human VEGF, plant expression, proteins, regeneration, cosmeceuticals.
Current Pharmaceutical Biotechnology
Title:Potential Application of Plant-derived Bioengineered Human VEGF for Tissue Regeneration
Volume: 17 Issue: 5
Author(s): Williams Laura, Lunello Pablo, Ajuria Arantxa, Bronchalo Isabel, Romualdo Alberto, Jurado Silvia, Canas Noelia, de Francisco Ana, Cobos Raquel and Orive Gorka
Affiliation:
Keywords: Growth Factor, recombinant human VEGF, plant expression, proteins, regeneration, cosmeceuticals.
Abstract: The design and development of novel biological drugs are among the most exciting new areas of biotechnology which are gaining the attention of scientists. In the last few decades several fabrication processes have been proposed and developed for the production of recombinant growth factors. However, traditional production processes have several limitations in terms of scale- up, cost-efficiency and purity grade of the proteins. In the present study, we propose for the first time the proof-of-concept of large-scale production of growth factors in plants as a new alternative to other production processes. We have decided to select vascular endothelial growth factor (VEGF) as model assuming its key role in cell survival and regenerative medicine. Results show that the present protocol is efficient to scale up a purification procedure of rh VEGF isoform 165 in Nicotiana benthamiana plants. Our procedure resulted in dimeric VEGF protein with high purity degree and yield, which showed full biological activity over endothelial and epithelial cells, suggesting great potential for its use in regenerative medicine. This protein could be exploited not only in tissue repair and regeneration but also as a biologically active ingredient in dermocosmetics.
Export Options
About this article
Cite this article as:
Laura Williams, Pablo Lunello, Arantxa Ajuria, Isabel Bronchalo, Alberto Romualdo, Silvia Jurado, Noelia Canas, de Francisco Ana , Raquel Cobos and Gorka Orive, Potential Application of Plant-derived Bioengineered Human VEGF for Tissue Regeneration, Current Pharmaceutical Biotechnology 2016; 17 (5) . https://dx.doi.org/10.2174/138920101705160303165312
DOI https://dx.doi.org/10.2174/138920101705160303165312 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Targets of Metformin in Cardioprotection: Beyond the Effects Mediated by AMPK
Current Pharmaceutical Design Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Stem Cells and Translational Medicine: From Research to Clinical Procedures
Current Tissue Engineering (Discontinued) 21.1 Tesla Magnetic Resonance Imaging Apparatus and Image Interpretation: First Report of a Scientific Advancement
Recent Patents on Medical Imaging Cardiac Dysfunction in Rats with Dietary-Induced Insulin Resistance Associated with Pharmacologically-induced Dyslipidemia
Current Pharmaceutical Design Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Editorial [Hot topic: New Perspectives in Cardiovascular Medicine (Executive Editor: Jaye P.F. Chin-Dusting)]
Current Pharmaceutical Design AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart
Current Cardiology Reviews EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
Current Vascular Pharmacology Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Therapy Against Reperfusion-induced Microvascular Injury
Current Pharmaceutical Design LPS In Patients With Left Ventricular Dysfunction Of Ischemic And Non-Ischemic Origin
Cardiovascular & Hematological Disorders-Drug Targets G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry